Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585464 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT04585464 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 127 participants.
The verdict
NCT04585464, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers. This Phase 1 study of EDG-5506 will assess the safety, tolerability, and pharmacokinetics (PK) and of EDG-5506 in adult healthy volunteers and in adults with Becker muscular dystrophy (BMD).
Interventions
- DRUG Placebo
- DRUG EDG-5506
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2020-10-12 |
| Est. Completion | 2021-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04585464
The ClinicalTrials.gov registry entry for NCT04585464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04585464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04585464 about?
NCT04585464 is a clinical study titled "A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults". EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers. This Phase 1 study of EDG-5506 will assess the safety, tolerability, and pharmacokinetics (PK) and of EDG-5506 in adult healthy volunteers and in adults with Becker muscular dystrophy (BMD).
What is the current status of trial NCT04585464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2020-10-12. Estimated completion is 2021-12-27.
What interventions are being tested in trial NCT04585464?
The interventions under investigation include: Placebo (DRUG), EDG-5506 (DRUG).
Who is sponsoring clinical trial NCT04585464?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.